BioCryst Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

BioCryst Pharmaceuticals

04/08/2025 14:31

BioCryst Pharmaceuticals Inc BCRX.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -6 cents.  The mean expectation of twelve analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -1 cents to 10 cents per share.

Revenue rose 49.4% to $163.35 million from a year ago; analysts expected $149.74 million.

BioCryst Pharmaceuticals Inc's reported EPS for the quarter was 2 cents​.

The company reported quarterly net income of $5.09 million.

BioCryst Pharmaceuticals Inc shares had fallen by 11.3% this quarter and gained 5.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 10.8% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $15.00, about 47% above its last closing price of $7.95

This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.01
0.04
Beat
Mar. 31 2025
-0.07
0.00
Beat
Dec. 31 2024
-0.06
-0.13
Missed
Sep. 30 2024
-0.06
-0.07
Missed